2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-126301
    DMT1 blocker 1 1354790-56-9 99.71%
    DMT1 blocker 1 is an orally active blocker of divalent metal transporter 1 (DMT1) with an IC50 of 0.64 μM. DMT1 blocker 1 inhibits intestinal cell absorption of non-heme iron, thereby alleviating iron overload by blocking the DMT1 transporter. DMT1 blocker 1 demonstrates significant efficacy in rodent models of acute iron hyperabsorption. DMT1 blocker 1 is useful for studying iron overload disorders such as hereditary hemochromatosis and thalassemia.
    DMT1 blocker 1
  • HY-128742
    Thiamine monophosphate chloride dihydrate 273724-21-3 99.24%
    Thiamine monophosphate chloride dihydrate is a vitamin B1 (HY-A0100) metabolite and thiamine precursor. Thiamine monophosphate chloride dihydrate is absorbable in vivo and can be converted into thiamine. Thiamine monophosphate chloride dihydrate can be used as a food additive.
    Thiamine monophosphate chloride dihydrate
  • HY-134194
    KL201 302939-48-6 98.18%
    KL201 a circadian clock modulator, is a isoform-selective cryptochrome 1 (CRY1) stabilizer. KL201 has no stabilizing effect on CRY2. KL201 lengthens the period of circadian rhythms in cells and tissues.
    KL201
  • HY-136717
    FBPase-1 inhibitor-1 883973-99-7 98.54%
    FBPase-1 inhibitor-1 (Compound 1) is an allosteric FBPase-1 inhibitor with an IC50 of 3.3 μM or 3.9 μM. FBPase-1 inhibitor-1 blocks gluconeogenesis by inhibiting FBPase-1. FBPase-1 inhibitor-1 can be used for the research of type 2 diabetes (t2dm).
    FBPase-1 inhibitor-1
  • HY-145086
    R-PSOP 1185189-97-2 99.41%
    R-PSOP is highly potent and selective nonpeptidic NMUR2 antagonist. R-PSOP binds to NMUR2 with the Kis of 52 and 32 nM for the human and rat NMUR2, respectively. R-PSOP shows moderate CNS penetration. R-PSOP can be used for the research of the eating disorders, obesity, pain, and stress-related disorders.
    R-PSOP
  • HY-14654S
    Aspirin-d3 921943-73-9 99.84%
    Aspirin-d3 is the deuterium labeled Aspirin (HY-14654). Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis.
    Aspirin-d3
  • HY-148065
    FMF-06-098-1 2769753-07-1 98.77%
    FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1.
    FMF-06-098-1
  • HY-150700
    RLX-33 2784577-71-3 99.79%
    RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome.
    RLX-33
  • HY-153340
    I-152 311343-11-0 98.78%
    I-152 is a conjugate containing N-acetyl-cysteine (NAC) and cysteamine (MEA). I-152 activates NRF2 and ATF4 signals. I-152 has anti-proliferative properties.
    I-152
  • HY-164781
    KOTX1 1788963-83-6 98.94%
    KOTX1 is an orally active and selective ALDH1A3 inhibitor. KOTX1 improves glucose tolerance, insulin secretion and blood sugar levels in diabetic mouse models.
    KOTX1
  • HY-B0218R
    Orlistat (Standard) 96829-58-2 98.21%
    Orlistat (Standard) is the analytical standard of Orlistat. This product is intended for research and analytical applications. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity. Anti-atherosclerotic effect.
    Orlistat (Standard)
  • HY-B1716S
    L-5-Hydroxytryptophan-d3 1276197-29-5 99.9%
    L-5-Hydroxytryptophan-d3 is the deuterium labeled L-5-Hydroxytryptophan. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist. L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia.
    L-5-Hydroxytryptophan-d3
  • HY-B1836A
    Meldonium dihydrate 86426-17-7 99.0%
    Meldonium (MET-88) dihydrate functions as a cardioprotective agent by cpmpetetively inhibiting γ-butyrobetaine hydroxylase (BBOX) and carnitine/organic cation transporter type 2 (OCTN2). Mildronate dihydrate exhibits IC50 values of 34-62 μM for human recombinant BBOX and an EC50 of 21 μM for human OCTN2. Meldonium dihydrate is a fatty acid oxidation inhibitor.
    Meldonium dihydrate
  • HY-N0805A
    Alisol B 18649-93-9 99.57%
    Alisol B is a triterpene with diverse biological activities. Alisol B binds human soluble epoxide hydrolase (sEH) with a Ki of 5.97 μM and reduces sEH activity. Alisol B inhibits RANKL-induced JNK phosphorylation, NFATc1 and c-Fos expression, osteoclast formation, mature osteoclast pit-forming and actin ring activity, and SERCA pump activity. Alisol B induces calcium mobilization, CaMKK-AMPK-mTOR pathway activation, autophagic flux, autophagosome formation, G1 phase cell cycle arrest, endoplasmic reticulum stress, unfolded protein responses, and cancer cell apoptosis. Alisol B can be used for the research of hypercalcemia, osteoporosis, rheumatoid arthritis, periodontitis, acute kidney injury, and breast cancer.
    Alisol B
  • HY-N1420A
    Rhamnose monohydrate 10030-85-0 ≥98.0%
    Rhamnose monohydrate (L-Rhamnose monohydrate) is an orally active deoxysugar. Rhamnose monohydrate can inhibit levels of pro-inflammatory interleukin and matrix metalloproteinases (MMPs) in skin aging models. Rhamnose can promote the phosphorylation levels of PKA substrates and HSL in SVF-derived adipocytes, stimulating PKA signaling. Rhamnose monohydrate can act against obesity in mice by stimulating fat dopamine receptors and inducing thermogenesis. Rhamnose monohydrate shows anti-aging effects. Rhamnose monohydrate can be used in the study of Ehrlich’s solid tumors and sarcomas.
    Rhamnose monohydrate
  • HY-N1902S
    4-Hydroxyphenylacetic acid-d6 100287-06-7 99.16%
    4-Hydroxyphenylacetic acid-d6 is the deuterium labeled 4-Hydroxyphenylacetic acid. 4-hydroxyphenylacetic acid, a major microbiota-derived metabolite of polyphenols, is involved in the antioxidative action. 4-hydroxyphenylacetic acid induces expression of Nrf2.
    4-Hydroxyphenylacetic acid-d6
  • HY-P1237A
    C-Type Natriuretic Peptide (CNP) (1-22), human TFA 1966153-17-2 99.07%
    C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor.
    C-Type Natriuretic Peptide (CNP) (1-22), human TFA
  • HY-P3584A
    (Pro3) GIP, human TFA 99.89%
    (Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with Ki/ Kd value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes.
    (Pro3) GIP, human TFA
  • HY-108398B
    11(Z),14(Z),17(Z)-Eicosatrienoic acid 17046-59-2 99.94%
    11(Z),14(Z),17(Z)-Eicosatrienoic acid is an unsaturated fatty acid that can maintain the continued replication of functional mitochondria in Saccharomyces cerevisiae (KD115).
    11(Z),14(Z),17(Z)-Eicosatrienoic acid
  • HY-113165A
    Isobutyryl-L-carnitine chloride 6920-31-6 98.0%
    Isobutyryl-L-carnitine chloride is a product of the acyl-CoA dehydrogenases.
    Isobutyryl-L-carnitine chloride
Cat. No. Product Name / Synonyms Application Reactivity